<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Individuals with severe forms of <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> suffer from <z:hpo ids='HP_0002719'>recurrent infections</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The therapeutic use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to increase the neutrophil count is associated with fewer <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> and an improved quality of life </plain></SENT>
<SENT sid="2" pm="."><plain>However, the long-term effects of this new therapy are largely unknown </plain></SENT>
<SENT sid="3" pm="."><plain>In particular, it is unclear if myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, a known complication of some forms of <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo>, will occur with increased frequency among patients who receive long-term treatment with hematopoietic growth factors </plain></SENT>
<SENT sid="4" pm="."><plain>We report 13 patients with <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorders</z:e> of myelopoiesis who developed leukemic transformation with either <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 1 who acquired a clonal cytogenetic abnormality without evidence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> while receiving rhG-CSF </plain></SENT>
<SENT sid="5" pm="."><plain>The bone marrows of 10 patients showed <z:mp ids='MP_0004026'>monosomy</z:mp> 7 and 5 had activating <z:mp ids='MP_0011356'>RAS</z:mp> mutations </plain></SENT>
<SENT sid="6" pm="."><plain>These abnormalities were not detected in pretreatment bone marrows and cessation of rhG-CSF was not associated with either clinical improvement or cytogenetic remission </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that patients with severe forms of <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> are at relatively high risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>The occurrence of <z:mp ids='MP_0004026'>monosomy</z:mp> 7 and <z:mp ids='MP_0011356'>RAS</z:mp> mutations in these cases suggests that the myeloid progenitors of some patients are genetically predisposed to <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The relationship between therapeutic rhG-CSF and <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> in patients with severe <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> is unclear </plain></SENT>
</text></document>